Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society

Research focused on Down syndrome has increased in the last several years to advance understanding of the consequences of trisomy 21 (T21) on molecular and cellular processes and, ultimately, on individuals with Down syndrome. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. The Third International Conference of T21RS, held June 6–9, 2019, in Barcelona, Spain, brought together 429 scientists, families, and industry representatives to share the latest discoveries on underlying cellular and molecular mechanisms of T21, define cognitive and behavioral challenges and better understand comorbidities associated with Down syndrome, including Alzheimer’s disease and leukemia. Presentation of cutting-edge results in neuroscience, neurology, model systems, psychology, cancer, biomarkers and molecular and pharmacological therapeutic approaches demonstrate the compelling interest and continuing advancement in all aspects of understanding and ameliorating conditions associated with T21.

[1]  Abigail L. Paulson,et al.  Multi-sensory Gamma Stimulation Ameliorates Alzheimer’s-Associated Pathology and Improves Cognition , 2019, Cell.

[2]  J. Pennings,et al.  Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome , 2018, Disease Models & Mechanisms.

[3]  N. Schupf,et al.  INDIVIDUAL DIFFERENCES IN LIFELONG ABILITIES MUST BE CONSIDERED FOR STAGING OF EARLY AD , 2017, Alzheimer's & Dementia.

[4]  Elena M. Vazey,et al.  Inhibitory designer receptors aggravate memory loss in a mouse model of down syndrome , 2020, Neurobiology of Disease.

[5]  P. D. De Deyn,et al.  Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society , 2018, Molecular Syndromology.

[6]  A. Granholm,et al.  Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome , 2017, Alzheimer's & Dementia.

[7]  G. Knott,et al.  In vivo modeling of human neuron dynamics and Down syndrome , 2018, Science.

[8]  M. Dierssen,et al.  Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions , 2020, Frontiers in Neuroscience.

[9]  S. Small,et al.  Neuronal lysosomal dysfunction releases exosomes harboring APP C-terminal fragments and unique lipid signatures , 2018, Nature Communications.

[10]  K. Blennow,et al.  “Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain” , 2020, bioRxiv.

[11]  A. Granholm,et al.  Exosome release and cargo in Down syndrome , 2019, Developmental neurobiology.

[12]  D. Butterfield,et al.  Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome , 2020, Neurobiology of Disease.

[13]  D. Mann,et al.  Patterns and severity of vascular amyloid in Alzheimer’s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer’s disease , 2018, Acta Neuropathologica.

[14]  K. Murai,et al.  Human iPSC-Derived Down Syndrome Astrocytes Display Genome-Wide Perturbations in Gene Expression, an Altered Adhesion Profile, and Increased Cellular Dynamics. , 2020, Human molecular genetics.

[15]  S. Finkbeiner.  The Autophagy Lysosomal Pathway and Neurodegeneration. , 2019, Cold Spring Harbor perspectives in biology.

[16]  J. Lawrence,et al.  Silencing Trisomy 21 with XIST in Neural Stem Cells Promotes Neuronal Differentiation. , 2020, Developmental cell.

[17]  P. McCallion,et al.  Supporting advanced dementia in people with Down syndrome and other intellectual disability: consensus statement of the International Summit on Intellectual Disability and Dementia. , 2018, Journal of intellectual disability research : JIDR.

[18]  T. Haydar,et al.  Longitudinal neuroanatomical and behavioral analyses show phenotypic drift and variability in the Ts65Dn mouse model of Down syndrome , 2020, Disease Models & Mechanisms.

[19]  B. Rothermel,et al.  Down Syndrome Critical Region 1 Gene, Rcan1, Helps Maintain a More Fused Mitochondrial Network , 2018, Circulation research.

[20]  Emery N. Brown,et al.  Author Correction: Gamma frequency entrainment attenuates amyloid load and modifies microglia , 2018, Nature.

[21]  P. Alapat,et al.  The Prevalence of OSA Among an Adult Population With Down Syndrome Referred to a Medical Clinic. , 2019, American journal on intellectual and developmental disabilities.

[22]  A. Danek,et al.  Alzheimer's disease in Down syndrome: An overlooked population for prevention trials , 2018, Alzheimer's & dementia.

[23]  C. Martínez-Cué,et al.  Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice , 2018, Brain, Behavior, and Immunity.

[24]  A. Lleó,et al.  Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. , 2018, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[25]  E. Macintyre,et al.  Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia , 2020, Clinical Cancer Research.

[26]  D. Bannerman,et al.  Mouse models of neurodegeneration: Know your question, know your mouse , 2019, Science Translational Medicine.

[27]  C. Wells,et al.  The Impact of APP on Alzheimer-like Pathogenesis and Gene Expression in Down Syndrome iPSC-Derived Neurons , 2018, Stem cell reports.

[28]  S. Antonarakis,et al.  Single cell transcriptome in aneuploidies reveals mechanisms of gene dosage imbalance , 2019, Nature Communications.

[29]  A. Shevchenko,et al.  Neocortical Expansion Due to Increased Proliferation of Basal Progenitors Is Linked to Changes in Their Morphology. , 2019, Cell stem cell.

[30]  Nicholas C. Firth,et al.  Aging related cognitive changes associated with Alzheimer's disease in Down syndrome , 2018, bioRxiv.

[31]  M. Dierssen,et al.  Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society , 2016, Molecular Syndromology.

[32]  Dean Nizetic,et al.  A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome , 2015, Nature Reviews Neuroscience.

[33]  C. Mokrysz,et al.  Predictors of Age of Diagnosis and Survival of Alzheimer’s Disease in Down Syndrome , 2017, Journal of Alzheimer's disease : JAD.

[34]  Dean Nizetic,et al.  Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP , 2018, Brain : a journal of neurology.

[35]  D. Nižetić,et al.  Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome , 2018, Alzheimer's & Dementia.

[36]  D. Nižetić,et al.  Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome , 2018, bioRxiv.

[37]  I. Rivera,et al.  Suppressing Aneuploidy-Associated Phenotypes Improves the Fitness of Trisomy 21 Cells , 2019, Cell reports.

[38]  D. Okuzaki,et al.  Elimination of protein aggregates prevents premature senescence in human trisomy 21 fibroblasts , 2019, PloS one.

[39]  Tiina K. Urv,et al.  Outcome Measures for Clinical Trials in Down Syndrome. , 2017, American journal on intellectual and developmental disabilities.

[40]  Rani K. Powers,et al.  Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors , 2019, Nature Communications.

[41]  S. Lehmann,et al.  Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study , 2020, The Lancet.

[42]  A. Coppus.  Comparing Generational Differences in Persons With Down Syndrome , 2017 .

[43]  W. Silverman,et al.  Dementia and mild cognitive impairment in adults with intellectual disability: issues of diagnosis. , 2013, Developmental disabilities research reviews.

[44]  C. Luchinat,et al.  Plasma metabolome and cognitive skills in Down syndrome , 2020, Scientific Reports.

[45]  J. Fortea,et al.  Consensus statement of the international summit on intellectual disability and Dementia related to post-diagnostic support* , 2018, Aging & mental health.

[46]  C. Martínez-Cué,et al.  Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes , 2017, Neurobiology of Disease.

[47]  Philip D. Gregory,et al.  Translating Dosage Compensation to Trisomy 21 , 2013, Nature.

[48]  J. Espinosa,et al.  Trisomy 21 Represses Cilia Formation and Function. , 2018, Developmental cell.